Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 3.11% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Poor long term growth as Net Sales has grown by an annual rate of 3.11% over the last 5 years
3
The company has declared Negative results for the last 5 consecutive quarters
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,103 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.30
-2.47%
0.89
Revenue and Profits:
Net Sales:
16,929 Million
(Quarterly Results - May 2025)
Net Profit:
-97 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.15%
0%
5.15%
6 Months
10.62%
0%
10.62%
1 Year
-10.61%
0%
-10.61%
2 Years
-16.25%
0%
-16.25%
3 Years
-20.27%
0%
-20.27%
4 Years
-28.24%
0%
-28.24%
5 Years
-31.13%
0%
-31.13%
Pharmarise Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.11%
EBIT Growth (5y)
-33.14%
EBIT to Interest (avg)
16.35
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
1.73
Sales to Capital Employed (avg)
3.12
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.02%
ROE (avg)
5.48%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.83
EV to EBIT
118.54
EV to EBITDA
11.57
EV to Capital Employed
0.94
EV to Sales
0.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.79%
ROE (Latest)
-2.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
16,929.00
15,313.00
10.55%
Operating Profit (PBDIT) excl Other Income
606.00
407.00
48.89%
Interest
59.00
38.00
55.26%
Exceptional Items
-118.00
5.00
-2,460.00%
Consolidate Net Profit
-97.00
12.00
-908.33%
Operating Profit Margin (Excl OI)
11.70%
3.10%
0.86%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - May'25
May'25
May'24
Change(%)
Net Sales
63,508.00
54,466.00
16.60%
Operating Profit (PBDIT) excl Other Income
1,788.00
2,086.00
-14.29%
Interest
178.00
66.00
169.70%
Exceptional Items
-211.00
-703.00
69.99%
Consolidate Net Profit
-381.00
-342.00
-11.40%
Operating Profit Margin (Excl OI)
4.60%
16.80%
-1.22%
USD in Million.
Net Sales
YoY Growth in year ended May 2025 is 16.60% vs 4.68% in May 2024
Consolidated Net Profit
YoY Growth in year ended May 2025 is -11.40% vs -198.56% in May 2024
About Pharmarise Holdings Corp. 
Pharmarise Holdings Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






